{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T14:53:10Z","timestamp":1774795990339,"version":"3.50.1"},"reference-count":69,"publisher":"Informa UK Limited","issue":"1","funder":[{"name":"UroGen Pharma and QED Therapeutics"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.2217\/fon-2021-0781","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T09:37:51Z","timestamp":1636709871000},"page":"105-115","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["Immunotherapy for Non-Muscle-Invasive Bladder Cancer: from the Origins of BCG to Novel Therapies"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7493-6464","authenticated-orcid":false,"given":"Samantha R","family":"Unsworth-White","sequence":"first","affiliation":[{"name":"Bladder Cancer Research Centre, Institute of Cancer &amp; Genomic Sciences, College of Medical &amp; Dental Sciences, University of Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1124-2940","authenticated-orcid":false,"given":"Mark O","family":"Kitchen","sequence":"additional","affiliation":[{"name":"School of Medicine, Keele, UK"},{"name":"Urology Department, University Hospitals of North Midlands NHS Trust, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2853-4293","authenticated-orcid":false,"given":"Richard T","family":"Bryan","sequence":"additional","affiliation":[{"name":"Bladder Cancer Research Centre, Institute of Cancer &amp; Genomic Sciences, College of Medical &amp; Dental Sciences, University of Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,11,12]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.06.010"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3817"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12032"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.06.028"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199508000-00007"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.04.006"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.2002.02776.x"},{"key":"e_1_3_2_10_1","unstructured":"Babjuk M BurgerM ComperatEet al. EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS) (2020). https:\/\/uroweb.org\/wp-content\/uploads\/EAU-Guidelines-on-Non-muscle-Invasive-Bladder-Cancer-2020.pdf"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1925.tb38960.x"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a121646"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200402-140OE"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/pmj.78.922.449"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/184291a0"},{"issue":"2","key":"e_1_3_2_16_1","first-page":"127","article-title":"Extracutaneous delayed hypersensitivity, particularly in the guinea-pig bladder","volume":"10","author":"Coe JE","year":"1966","unstructured":"Coe JE , FeldmanJD. Extracutaneous delayed hypersensitivity, particularly in the guinea-pig bladder. Immunology10(2), 127\u201336 (1966).","journal-title":"Immunology"},{"key":"e_1_3_2_17_1","first-page":"271","article-title":"Immunotherapy of cancer: regression of tumours after intralesional injection of living Mycobacterium bovis","volume":"172","author":"Zbar B","year":"1971","unstructured":"Zbar B , TanakaT. Immunotherapy of cancer: regression of tumours after intralesional injection of living Mycobacterium bovis. Am. Assoc. Adv. Sci.172, 271\u2013273 (1971).","journal-title":"Am. Assoc. Adv. Sci."},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197511)36:5<1662::AID-CNCR2820360520>3.0.CO;2-6"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)58737-6"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.08.122"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64273-5"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)43125-9"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.3.441"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67707-5"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64043-8"},{"key":"e_1_3_2_26_1","unstructured":"Babjuk M BurgerM ComperatE. EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS) (2018). https:\/\/uroweb.org\/wp-content\/uploads\/EAU-Guidelines-Non-muscle-invasive-Bladder-Cancer-TaT1-CIS-2018.pdf"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.01.086"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2018.08.19"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.12.024"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.02.061"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.4103\/0974-7796.106873"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1159\/000440701"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.10.021"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2018.08.015"},{"key":"e_1_3_2_35_1","unstructured":"Balar AV . Faced with BCG shortages oncologists move to rationing of care (2019). www.targetedonc.com\/view\/faced-with-bcg-shortages-oncologists-move-to-rationing-of-care"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.11.031"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.79"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2007.01696.x"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0000000000000739"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.296.6639.1759"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199010000-00002"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1308\/003588414X13946184901001"},{"key":"e_1_3_2_43_1","unstructured":"Clinicaltrial.gov . Electromotive mitomycin-C (EMDA-MMC) in preventing recurrences in high-risk non-muscle-invasive bladder cancer (FB10) (2018). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03664869"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70472-1"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1086\/314064"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.10.039"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.02.040"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.04.066"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.04.062"},{"key":"e_1_3_2_50_1","unstructured":"US Food and Drug Administration . BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment (2018). www.fda.gov\/media\/101468\/download"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-150008"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-170126"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000688"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.79"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00147-9"},{"key":"e_1_3_2_56_1","unstructured":"Clinicaltrials.gov . Assessment of efficacy and safety of durvalumab plus BCG compared to the standard therapy with bcg in non-muscle invasive bladder cancer (POTOMAC) (2020). www.clinicaltrials.gov\/ct2\/show\/NCT03528694"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2013.153"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1526250"},{"issue":"7","key":"e_1_3_2_59_1","first-page":"65","article-title":"Immunotherapy for bladder cancer","volume":"4","author":"Fuge O","year":"2015","unstructured":"Fuge O , VasdevN, AllchorneP, GreenJA. Immunotherapy for bladder cancer. Res. Rep. Urol.4(7), 65\u201379 (2015).","journal-title":"Res. Rep. Urol."},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.11.150"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.11.019"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2004.05.027"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700865"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.3064"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30540-4"},{"key":"e_1_3_2_66_1","unstructured":"Dickstein R WuN CowanBet al. VISTA phase 3 trial of vicinium an EPCAM-targeted pseudomonas exotoxin in BCG-unresponsive non-muscle invasive bladder cancer (2018). https:\/\/abstracts.mirrorsmed.org\/abstracts\/vista-phase-3-trial-vicinium-epcam-targeted-pseudomonas-exotoxin-bcg-unresponsive-non"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1189"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01232"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2019.905"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.04.023"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30147-9"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2021-0781","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:47:40Z","timestamp":1719125260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2021-0781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,12]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.2217\/fon-2021-0781"],"URL":"https:\/\/doi.org\/10.2217\/fon-2021-0781","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-06-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}